14^th International Conference on Chronic Obstructive Pulmonary Disease December 05-06, 2022 Rome, Italy

Track 1: Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease is one of the leading causes of disability and death worldwide. COPD exacerbation is usually treated with antibiotics, systemic corticosteroids, and inhaled bronchodilators. COPD exacerbation was treated repeatedly with standard therapy. Dynamic expiratory computed tomography of the chest was done, which revealed concomitant tracheomalacia. COPD and tracheomalacia may coexist during recurrent exacerbations of COPD, and delayed diagnosis can be associated with severe comorbidities. Ordering the appropriate imaging technique may aid in the correct diagnosis and facilitate appropriate management. COPD Conferences will survey the evolution of pulmonology.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies:

Italian Society for Infant Respiratory Diseases; Association for Respiratory Technology and Physiology; Italian Society of Pneumology; The Primary Care Respiratory Society UK; European COPD Coalition; European Lung Foundation

USA COPD Societies:

American Thoracic Society; American Lung Association; American Association for Respiratory Care; American College of Chest Physicians; Brazilian Association of Cardiorespiratory Physiotherapy and Physical Therapy in Intensive Care

Asian COPD Societies:

Thoracic Society of Australia and New Zealand; Chinese Thoracic Society; Chinese Association of Chest Physicians; Indian Chest Society; Japanese Respiratory Society

Track 2: COPD Pathogenesis

Inflammation is present in the lungs, especially the small airway routes, of all people who smoke. COPD Pathogenesis is typical defensive reaction to the inhaled toxins is enhanced in COPD, leading to tissue destruction, debilitation of the defence mechanisms and interruption of the repair mechanisms. In general, the inflammatory and structural changes in the airway routes increased with disease seriousness and hold on even after smoking cessation. Other than inflammation, two different procedures are associated with the pathogenesis of COPD an irregularity amongst proteases and antiproteases and an imbalance amongst oxidants and antioxidants agents in the lungs. Pulmonary Conferences expresses various developing treatments for COPD.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies:

European Society of Federasma and Allergies; Cystic Fibrosis Europe; British Lung Foundation; Italian Society for Infant Respiratory Diseases; Association for Respiratory Technology and Physiology; Italian Society of Pneumology

USA COPD Societies:

Brazilian Society of Pneumology and Tisiology; Canadian Thoracic Society; Argentine Association of Respiratory Medicine; Chilean Society of Respiratory Diseases; Croation Respiratory Society

Asian COPD Societies:

Philippine College of Chest Physicians; Korean Academy of Tuberculosis and Respiratory Diseases; Turkish Thoracic Society; Turkish Respiratory Society; Saudi Thoracic Society

Track 3: Asthma and COPD

Bronchial Asthma and Chronic Obstructive Pulmonary Disease are obstructive pneumonic sicknesses that influenced a large number of people everywhere throughout the world. Chronic Obstructive Pulmonary Disease (COPD) is a group of pulmonary diseases that block air stream in the lungs. Asthma is a chronic disease noticeable by spasms of bronchi, due to inflamed and narrowed airways in the lungs. Asthma causes difficulty in breathing that often results from an allergic reaction. There is large evidence that treatment with anti-inflammatory drugs reduces morbidity and mortality in asthma. Inhaled corticosteroids appear to have a place in the management of severe chronic obstructive pulmonary disease, perhaps by decreasing the frequency of exacerbations. Lung Conferences envelop the fields of asthma and COPD which have important similarities and differences. Asthma and COPD are chronic inflammatory diseases that include the little airway routes and cause airflow impediment, both result from gene environment communications and both are typically characterized by mucus and bronchoconstriction.

COPD Conferences | Pulmonary Conferences | Lung Conferences

 April 11-14, 2020 Genève, Switzerland; Interstitial Lung Diseases Conferences, April 18-20, 2020 Heidelberg, Germany; 5th International Asthma Conferences and COPD Conferences January 18-20, 2020 Berlin, Germany

European COPD Societies:

The Primary Care Respiratory Society UK; European COPD Coalition; European Lung Foundation; Romanian Society of Pneumology; European Respiratory Society; European Federation of Allergy and Airways Diseases Patient Associations

USA COPD Societies:

Peruvian Society of Pneumology; American Thoracic Society; American Lung Association; American Association for Respiratory Care; American College of Chest Physicians

Asian COPD Societies:

Thoracic Society of Australia and New Zealand; Chinese Thoracic Society; Chinese Association of Chest Physicians; Indian Chest Society; Japanese Respiratory Society

Track 4: Epidemiology of COPD

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease in responsible for human and economic burden around the world. Cigarette smoking is the fundamental hazard factor for COPD in the developed world, although other essential respiratory disorder incorporate word related exposures, air contamination, airway route hyper responsiveness, asthma, and hereditary predisposition. In the vast majority of the world, Epidemiology of COPD prevalence and mortality keep on rising in light of increases in smoking addiction, especially by women and adolescents. COPD is likewise an imperative reason for disability, and is connected to comorbid diseases, for example, depression and cardiovascular disease, which adds to the large economic burden related with this issue. Better public health and medical intercessions that target both the risk factors for COPD and look toward prior mediation may decrease growing public health impact of COPD. COPD Conferences will focus on the understanding of all the pulmonary treatments.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies:

European Idiopathic Pulmonary Fibrosis & Related Disorders Federation; European Pulmonary Hypertension Association; European Association for Bronchology and Interventional Pulmonology; European Society of Federasma and Allergies; Cystic Fibrosis Europe; British Lung Foundation

USA COPD Societies:

Brazilian Association of Cardiorespiratory Physiotherapy and Physical Therapy in Intensive Care; Brazilian Society of Pneumology and Tisiology; Canadian Thoracic Society; Argentine Association of Respiratory Medicine; Chilean Society of Respiratory Diseases

Asian COPD Societies:

Philippine College of Chest Physicians; Korean Academy of Tuberculosis and Respiratory Diseases; Turkish Thoracic Society; Turkish Respiratory Society; Saudi Thoracic Society

Track 5: COPD Therapeutics

The objective of COPD therapeutics is to enhance a patient's functional status and quality by protecting optimal lung function, enhancing indications, and keeping the recurrence of COPD exacerbations. At present, no medicines aside from lung transplantation have been appeared to significantly enhance lung function or decrease mortality; however, oxygen therapy and smoking cessation may decrease mortality. Once the diagnosis of COPD is established, it is essential to educate the patient about the sickness and to empower their active interest in treatment. Bronchodilators are the foundation of any COPD treatment regimen. They work by enlarging aviation routes, accordingly diminishing airsac protection. Pulmonary Conferences provides a multidisciplinary to pulmonology researchers.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies:

Italian Society for Infant Respiratory Diseases; Association for Respiratory Technology and Physiology; Italian Society of Pneumology; The Primary Care Respiratory Society UK; European COPD Coalition; European Lung Foundation

USA COPD Societies:

Croation Respiratory Society; Peruvian Society of Pneumology; American Thoracic Society; American Lung Association; American Association for Respiratory Care

Asian COPD Societies:

Chinese Thoracic Society; Chinese Association of Chest Physicians; Indian Chest Society; Japanese Respiratory Society; Thoracic Society of Australia and New Zealand

Track 6: COPD Exacerbations

Constant Obstructive Pulmonary Disease (COPD) experiences long-term and dynamic damage to their lungs. This impacts air flow to the lungs. Doctors in some cases call this condition chronic bronchitis or chronic emphysema. Those with COPD can experience periods when their signs are much worse than normal. This is known as an acute exacerbation. Shortness of breath and chest tightness is present in many cases. A patient encountering a COPD exacerbation may need to search for medicinal help at a hospital. COPD exacerbations can be harmful because they can make damage to the lungs. COPD, keeping a compounding from happening can enable you to live a healthier life and diminish risk of death. Self-management and prevention for COPD will be beneficial for future exacerbation. Lung Conferences will explore the application of pulmonology.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies:

European Respiratory Society; European Idiopathic Pulmonary Fibrosis & Related Disorders Federation; European Association for Bronchology and Interventional Pulmonology; Cystic Fibrosis Europe; Italian Society for Infant Respiratory Diseases; Italian Society of Pneumology

USA COPD Societies:

American College of Chest Physicians; Brazilian Association of Cardiorespiratory Physiotherapy and Physical Therapy in Intensive Care; Brazilian Society of Pneumology and Tisiology; Canadian Thoracic Society; Argentine Association of Respiratory Medicine

Asian COPD Societies:

Turkish Respiratory Society; Korean Academy of Tuberculosis and Respiratory Diseases; Japanese Respiratory Society; Chinese Association of Chest Physicians; Indian Chest Society

Track 7: Types of COPD

People with different types of COPD experience difficulty in breathing and shortness of breath. The two principle infections that fall under the extent of COPD are: Chronic bronchitis, which involves a long-term cough with mucus, it is a long-term inflammation of the bronchi, which results in increased production of mucus, as well as other changes. These changes may result in breathing problems, frequent infections, cough, disability, anxiety and depression. Emphysema, which involves damage to the lungs over time. Emphysema is a chronic lung condition in which alveoli may be: destroyed, narrowed, collapsed, stretched, and over-inflated. This can cause a reduction in respiratory capacity and breathlessness. Harm to the air sacs is irreversible and brings about permanent "holes" in the lung tissue. COPD Conferences will focus on the different techniques used in pulmonology.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies:      

Romanian Society of Pneumology; European Federation of Allergy and Airways Diseases Patient Associations; European Pulmonary Hypertension Association; European Society of Federasma and Allergies; British Lung Foundation; Association for Respiratory Technology and Physiology

USA COPD Societies:

Chilean Society of Respiratory Diseases; Croation Respiratory Society; Peruvian Society of Pneumology; American Thoracic Society; American Lung Association

Asian COPD Societies:

Thoracic Society of Australia and New Zealand; Saudi Thoracic Society; Chinese Thoracic Society; Turkish Respiratory Society; Korean Academy of Tuberculosis and Respiratory Diseases

Track 8: COPD: Sign and Symptoms

For Chronic Obstructive Pulmonary Disease there are no sign and symptoms or sometimes it may show mild symptoms. As the disease gets inferior, symptoms usually progress more severe. The first symptom of COPD is usually a long-term or chronic cough. If you have COPD, you also may often have colds or other respiratory infections such as the flu, or influenza. Pulmonary Conferences discuss about the COPD symptoms, often don't appear until significant lung damage or lung cancer has occurred, and they usually worsen over time, particularly if smoking exposure continues. Symptoms include increasing breathlessness – this may just occur when exercising at first and you may sometimes wake up at night feeling breathless, a persistent chesty cough with phlegm that never seems to go away, frequent chest infections, persistent wheezing.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies:

European Lung Foundation; The Primary Care Respiratory Society UK; European COPD Coalition; Association for Respiratory Technology and Physiology; Italian Society for Infant Respiratory Diseases; Cystic Fibrosis Europe

USA COPD Societies:

American Association for Respiratory Care; American College of Chest Physicians; Brazilian Association of Cardiorespiratory Physiotherapy and Physical Therapy in Intensive Care; Brazilian Society of Pneumology and Tisiology; Canadian Thoracic Society

Asian COPD Societies:

Japanese Respiratory Society; Philippine College of Chest Physicians; Korean Academy of Tuberculosis and Respiratory Diseases; Chinese Thoracic Society; Indian Chest Society

Track 9: Genetic risk factor of COPD

Even if an individual has never smoked or been unprotected to pollutants for an extended period of time, they can still develop COPD. Alpha-1 Antitrypsin Deficiency (AATD) is the most commonly known genetic risk factor of COPD in emphysema. Alpha-1 Antitrypsin related COPD is caused by a deficiency of the Alpha-1  in the bloodstream. Without the Alpha-1 Antitrypsin protein, white blood cells begin to harm the lungs and lung deterioration occurs. The World Health Organization and the American Thoracic Society suggests that each individual determined to have COPD be tested for Alpha-1. Pulmonary Conferences also discusses about different types of genes which may be a cause of pulmonary diseases.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies:

Romanian Society of Pneumology; European Respiratory Society; European Federation of Allergy and Airways Diseases Patient Associations; European Lung Foundation; the Primary Care Respiratory Society UK; Italian Society of Pneumology

USA COPD Societies:

Argentine Association of Respiratory Medicine; Chilean Society of Respiratory Diseases; Croation Respiratory Society; Peruvian Society of Pneumology; American Thoracic Society

Asian COPD Societies:

Thoracic Society of Australia and New Zealand; Philippine College of Chest Physicians; Saudi Thoracic Society; Indian Chest Society; Chinese Thoracic Society

Track 10: Lung cancer

Patients with chronic obstructive pulmonary disease are at increased risk for both the development of primary lung cancer, as well as poor outcome after lung cancer diagnosis and treatment. Because of existing impairments in lung function, patients with COPD often do not meet traditional criteria for tolerance of definitive surgical lung cancer therapy. Emerging information with respect to the pathophysiology of COPD in lung resection demonstrates that postoperative decrements in lung capacity may be less than anticipated by traditional prediction tools. In patients with COPD, more inclusive consideration for surgical resection with curative intent might be appropriate as constrained surgical resections or nonsurgical therapeutic options provide inferior survival. Besides, optimizing perioperative COPD therapeutic care as indicated by clinical practice rules including smoking cessation can possibly minimize morbidity and enhance functional status in this often severely impaired patient population. Lung Conferences concentrates on the risk factor for development of lung cancer.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies:

European Federation of Allergy and Airways Diseases Patient Associations; European Idiopathic Pulmonary Fibrosis & Related Disorders Federation; European Pulmonary Hypertension Association; European Association for Bronchology and Interventional Pulmonology; European Society of Federasma and Allergies; British Lung Foundation               

USA COPD Societies:

American Lung Association; American Association for Respiratory Care; American College of Chest Physicians; Brazilian Association of Cardiorespiratory Physiotherapy and Physical Therapy in Intensive Care; Brazilian Society of Pneumology and Tisiology

Asian COPD Societies:

Turkish Respiratory Society; Korean Academy of Tuberculosis and Respiratory Diseases; Japanese Respiratory Society; Chinese Association of Chest Physicians; Thoracic Society of Australia and New Zealand

Track 11: COPD and Cardiovascular Diseases

Chronic obstructive pulmonary disease is related with increased risk of cardiovascular disease, for example, heart failure or a heart attack. The lungs and the heart work firmly together to supply the oxygen; oxygen in the air that comes into the lungs is moved into the circulation system, which the heart at that point pushes out to rest of the body. But diseases in both the heart and the lungs often go together. If person have COPD then there is a higher risk of having cardiovascular diseases. Comorbidities and chronic obstructive pulmonary disease (COPD) are pervasive, with cardiovascular disease being the most well-known and significant. Risk factors for COPD and Cardiovascular Diseases, such as smoking, low socioeconomic class, and a sedentary lifestyle contribute to the natural history of each of these conditions. COPD Conferences will focus on the scope of COPD related to cardiovascular diseases.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies:

Italian Society for Infant Respiratory Diseases; Association for Respiratory Technology and Physiology; Italian Society of Pneumology; The Primary Care Respiratory Society UK; European COPD Coalition; European Lung Foundation

USA COPD Societies:

Canadian Thoracic Society; Argentine Association of Respiratory Medicine; Chilean Society of Respiratory Diseases; Croation Respiratory Society; Peruvian Society of Pneumology

Asian COPD Societies:

Chinese Thoracic Society; Indian Chest Society; Chinese Association of Chest Physicians; Japanese Respiratory Society; Philippine College of Chest Physicians

Track 12: Pulmonary Hypertension

Pulmonary hypertension is a type of high blood pressure that impacts the arteries in lungs and the right side of heart. In one type of pulmonary hypertension, modest arteries in lungs, called pulmonary arterioles, and capillaries become narrowed, blocked or destroyed. This makes it harder for blood to flow through lungs, and raises pressure inside the arteries of lungs. As the pressure builds, heart's lower right chamber (right ventricle) must work harder to direct blood through lungs, in the end causing heart muscle to debilitates and fail. Few categories of pulmonary hypertension are serious conditions that become progressively worse and sometimes become fatal. Pulmonary hypertension can lead to a number of COPD complications such as blood clots in the lungs, sickle cell disease and sleep apnea. Although a few kinds of pulmonary hypertension are not curable, treatment can help decrease symptoms and enhance quality of life. Pulmonary Conferences concentrates on the impact of pulmonary hypertension.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies:

Cystic Fibrosis Europe; European Pulmonary Hypertension Association; European Association for Bronchology and Interventional Pulmonology; European Society of Federasma and Allergies; Romanian Society of Pneumology; European Respiratory Society

USA COPD Societies:

American Thoracic Society; American Lung Association; American Association for Respiratory Care; American College of Chest Physicians; Brazilian Association of Cardiorespiratory Physiotherapy and Physical Therapy in Intensive Care

Asian COPD Societies:

Thoracic Society of Australia and New Zealand; Chinese Association of Chest Physicians; Japanese Respiratory Society; Korean Academy of Tuberculosis and Respiratory Diseases; Turkish Respiratory Society

Track 13: Pathophysiology of COPD

Chronic obstructive pulmonary disease (COPD) is a life-threatening condition. It affects lungs and ability to breathe. The pathophysiology of COPD is the physical changes associated with it, start with damage to airways and the air sacs in lungs. It progresses from a cough with mucus to difficulty breathing. To understand pathophysiology of COPD, it is essential to understand the structure of the lungs. When you inhale, air moves down in trachea through two tubes called bronchi. The bronchi branch out into smaller tubes called bronchioles. At the ends of the bronchioles are little air sacs called alveoli. And at the end of alveoli are capillaries, which are tiny blood vessels. Lung Conferences envision the pulmonology.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies:

European COPD Coalition; The Primary Care Respiratory Society UK; Italian Society of Pneumology; Association for Respiratory Technology and Physiology; Italian Society for Infant Respiratory Diseases; British Lung Foundation

USA COPD Societies:

Brazilian Society of Pneumology and Tisiology; Canadian Thoracic Society; Argentine Association of Respiratory Medicine; Chilean Society of Respiratory Diseases; Croation Respiratory Society

Asian COPD Societies:

Saudi Thoracic Society; Korean Academy of Tuberculosis and Respiratory Diseases; Turkish Thoracic Society; Turkish Respiratory Society; Indian Chest Society

Track 14: Co-Morbidities of COPD

Additional pulmonary comorbidities impact the anticipation of patients with COPD. Tobacco smoking is a typical hazard factor for much comorbidity, including coronary illness, heart failure and lung cancer. Comorbidities, for example, pulmonary artery disease and malnutrition are specifically caused by COPD, while others, such as fundamental venous thromboembolism, anxiety, depression, osteoporosis, obesity, metabolic disorder, diabetes, sleep disturbance and anaemia, have no clear physiopathological association with COPD. Co-Morbidities of COPD shared conviction between the majorities of these extra pulmonary signs is chronic systemic inflammation. These diseases potentiate the morbidity of COPD, prompting expanded hospitalisations and healthcare costs. They can frequently cause death, independently of respiratory failure. Comorbidities make the management of COPD difficult and should be evaluated and treated adequately. COPD Conferences enlighten the recent advances in COPD and pulmonology research.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies:

European Federation of Allergy and Airways Diseases Patient Associations; European Idiopathic Pulmonary Fibrosis & Related Disorders Federation; The Primary Care Respiratory Society UK; Italian Society of Pneumology; Romanian Society of Pneumology; European Lung Foundation

USA COPD Societies:

Peruvian Society of Pneumology; American Thoracic Society; American Lung Association; American Association for Respiratory Care; American College of Chest Physicians

Asian COPD Societies:

Chinese Thoracic Society; Thoracic Society of Australia and New Zealand; Chinese Association of Chest Physicians; Indian Chest Society; Philippine College of Chest Physicians

Track 15: COPD Complications

Individuals with COPD can be in risk for serious complications that can not only put their health in jeopardy, but can also be fatal. Cor Pulmonale of COPD bring down extremity edema (swelling) in a patient with COPD Complications is typically an indication of cor pulmonale (pulmonary hypertension and right-sided heart failure). Acute COPD Exacerbations are portrayed by an unexpected increment of manifestations. Cough and sputum production increases. At the point when respiratory failure happens in a patient who slowly, there is a moderate decrease in lung capacity and rising levels of carbon dioxide in the blood. The expanding carbon dioxide makes an opiate impact in the patient, who gradually loses awareness and quits relaxing. Different difficulties of COPD incorporate pneumonia, polycythemia, and pneumothorax. Pneumonia caused by bacterial disease can prompt respiratory failure in these patients. Streptococcus pneumoniae is the most well-known reason for bacterial pneumonia in patients with COPD. Pneumothorax happens when a hole develops in the lung, enabling air to escape into the space between the lung and the chest wall and collapsing the lung. Polycythemia in COPD is the body's endeavour to adjust to decreased amount of blood oxygen by expanding the generation of oxygen-conveying red blood cells. While this might be useful temporarily, overproduction eventually clogs small blood vessels. COPD Conferences provides global forum for discussion about new innovation of pulmonology research.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies:

European Pulmonary Hypertension Association; European Association for Bronchology and Interventional Pulmonology; European Society of Federasma and Allergies; Cystic Fibrosis Europe; British Lung Foundation; Italian Society for Infant Respiratory Diseases

USA COPD Societies:

Brazilian Association of Cardiorespiratory Physiotherapy and Physical Therapy in Intensive Care; Brazilian Society of Pneumology and Tisiology; Canadian Thoracic Society; Argentine Association of Respiratory Medicine; Chilean Society of Respiratory Diseases

Asian COPD Societies:

Thoracic Society of Australia and New Zealand; Saudi Thoracic Society; Chinese Thoracic Society; Turkish Respiratory Society; Korean Academy of Tuberculosis and Respiratory Diseases

Track 16: Pulmonary diseases-treatment and therapies

There's currently no cure for chronic obstructive pulmonary disease (COPD), yet pulmonary diseases treatment and therapies can help moderate the movement of the condition and control the side effects. Medicines include: quit smoking, inhalers and pharmaceuticals – to help make breathing easier, pulmonary rehabilitation – a specific program of exercise and education surgery or a lung transplant – although this is only an option for a very small number of people. Much of the treatment for COPD includes self-management and prevention of COPD. Oxygen therapy can improve quality of life and is the only COPD therapy proven to extend life. Surgery is an option for some people with some forms of severe emphysema who aren't helped sufficiently by medications alone. Surgical options include: Lung volume reduction surgery, Lung transplant and Bullectomy. COPD Conferences will disclose the application of different treatments and therapies.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies:

European Idiopathic Pulmonary Fibrosis & Related Disorders Federation; European Pulmonary Hypertension Association; European Association for Bronchology and Interventional Pulmonology; European Society of Federasma and Allergies; Cystic Fibrosis Europe; British Lung Foundation

USA COPD Societies:

Croation Respiratory Society; Peruvian Society of Pneumology; American Thoracic Society; American Lung Association; American Association for Respiratory Care

Asian COPD Societies:

Chinese Thoracic Society; Chinese Association of Chest Physicians; Indian Chest Society; Japanese Respiratory Society; Thoracic Society of Australia and New Zealand

Track 17: Pediatric Pulmonary, Critical care and Sleep

Much of the focus of pulmonary rehabilitation, research and pneumonic medication goes toward the youngest individuals from society-the newborns. For instance, the reason for pulmonary stenosis is because of improper pulmonary valve improvement in the initial two months of fetal development. It's congenital but treatable. With a sound pulmonary stenosis diagnosis the heart valve can be replaced or repaired and children can grow to lead normal healthy lives. Sleep apnea affects premature babies. A situation called apnea of prematurity exists when the child doesn’t breath for 20 seconds or more. It is a pulmonary disease that can be treated with ventilation machines and medications. COPD Conferences explains about pediatric pulmonary, critical care and sleep which includes Pediatric emergencies, Pneumonia, Respiratory failure, Pediatric in-patient and critical care, Sepsis and Head Trauma & Concussion.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies:

Association for Respiratory Technology and Physiology; Italian Society of Pneumology; The Primary Care Respiratory Society UK; European COPD Coalition; European Lung Foundation; Italian Society for Infant Respiratory Diseases

USA COPD Societies:

American College of Chest Physicians; Brazilian Association of Cardiorespiratory Physiotherapy and Physical Therapy in Intensive Care; Brazilian Society of Pneumology and Tisiology; Canadian Thoracic Society; Argentine Association of Respiratory Medicine

Asian COPD Societies:

Turkish Respiratory Society; Korean Academy of Tuberculosis and Respiratory Diseases; Japanese Respiratory Society; Chinese Association of Chest Physicians; Indian Chest Society

Track 18: Depression and anxiety in COPD

Depression and anxiety in COPD are regular in patients with chronic obstructive pulmonary disease (COPD), assessments of their pervasiveness differ significantly. These likely reflect the assortment of scales and strategies used to measure such symptoms. Patients with COPD with three or more comorbidities are more likely to be frequently hospitalized and may die prematurely compared to COPD patients without comorbidities.  An uplifted experience of dyspnoea is probably contributing component to anxiety. Feelings of depression may be precipitated by the loss and grief associated with the disability of COPD. Smoking has been associated with nicotine addiction, and the factors that contribute to smoking may also predispose to anxiety and depressive disorders. The cause of depression and anxiety symptoms are multifactorial and include behavioural, social and biological factors. Lung Conferences exhibits randomized controlled trials show that activity exercise training and precisely chose pharmacological treatment are regularly effective in ameliorating anxiety and depression.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies:

European Society of Federasma and Allergies; Cystic Fibrosis Europe; British Lung Foundation; Italian Society for Infant Respiratory Diseases; Association for Respiratory Technology and Physiology; Italian Society of Pneumology

USA COPD Societies:

Chilean Society of Respiratory Diseases; Croation Respiratory Society; Peruvian Society of Pneumology; American Thoracic Society; American Lung Association

Asian COPD Societies:

Thoracic Society of Australia and New Zealand; Philippine College of Chest Physicians; Saudi Thoracic Society; Indian Chest Society; Chinese Thoracic Society

Track 19: Drug Discovery of COPD

Chronic obstructive pulmonary disease is an increasing worldwide medical issue and cause of death. COPD predominantly influencing small airway routes and lung parenchyma that prompts dynamic aviation route deterrent. COPD is a standout amongst the most widely recognized infections on the globe, and there is a global increase in prevalence, however there are no drugs available at present that halt the relentless progression of this disease. In any case, a superior comprehension of the cell and molecular mechanisms that are associated with the underlying inflammatory and destructive processes has uncovered a few new focuses for which drugs are presently being developed, and the prospects for finding new medications are good.

European COPD Societies:

European Society of Federasma and Allergies; Cystic Fibrosis Europe; British Lung Foundation; Italian Society for Infant Respiratory Diseases; Association for Respiratory Technology and Physiology; Italian Society of Pneumology

USA COPD Societies:

Chilean Society of Respiratory Diseases; Croation Respiratory Society; Peruvian Society of Pneumology; American Thoracic Society; American Lung Association

Asian COPD Societies:

Thoracic Society of Australia and New Zealand; Philippine College of Chest Physicians; Saudi Thoracic Society; Indian Chest Society; Chinese Thoracic Society

Track 20: Self-Management and Prevention of COPD

Self-Management and Prevention of COPD interventions help patients with chronic obstructive pulmonary disease (COPD) acquire and practise the skills they need to carry out disease-specific medical regimens, guide changes in health behaviour and provide emotional support to enable patients to control their disease. Patients with COPD confirmed by spirometry and symptoms and airflow obstruction should be monitored regularly to guide modification of treatment and to identify complications early Pulmonary Conferences will be focused on the self-management support programmes should be collaborative between healthcare professionals and patients, to help them acquire skills to understand and manage their medications and exacerbations of COPD, adopt healthier behaviours and manage the social-emotional consequences of the disease.

COPD Conferences | Pulmonary Conferences | Lung Conferences

European COPD Societies:

Romanian Society of Pneumology; European Respiratory Society; European Federation of Allergy and Airways Diseases Patient Associations; European Idiopathic Pulmonary Fibrosis & Related Disorders Federation; European Pulmonary Hypertension Association; European Association for Bronchology and Interventional Pulmonology

USA COPD Societies:

Chilean Society of Respiratory Diseases; Croation Respiratory Society; Peruvian Society of Pneumology; American Thoracic Society; American Lung Association

Asian COPD Societies:

Philippine College of Chest Physicians; Korean Academy of Tuberculosis and Respiratory Diseases; Turkish Thoracic Society; Turkish Respiratory Society; Saudi Thoracic Society

Conference series llc LTD. invites all the participants through the globe to join at CME Accredited "14^th International Chronic Obstructive Pulmonary Disease Conference"which is going to held during  December 05-06, 2022 Rome, Italy which will include keynote sessions, Oral presentation, Poster presentation and Exhibitions. The main theme of the conference is “Delving into the advances in COPD research” which covers current and developing research on Pulmonology.

For more details please visit: https://copd.insightconferences.com/

Importance & Scope

Chronic obstructive pulmonary disease (COPD) is the fourth leading causes of death in the world. Moreover, among the top five causes of death, this disease is the only one with increasing mortality rates. COPD is an essential public health problem in many countries which is evaluated to become the fifth reason for disability. COPD is a common condition that mainly affects aged or adults who smoke. The condition cannot be cured or reversed, but for many people treatment can help them to keep it under control so it does not affect their daily activities. COPD Conference 2022 is to understand the depth of the disease and proceed for the future research.

The COPD Conference 2022 will discover the new concepts and informative session program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We delightedly invite you to join us at the COPD Conference 2022, where you will have essential experience with scholars from around the world. All members from COPD Conference 2022organizing committee look forward to meet you in Rome, Italy.

Market Analysis Report:        

Increasing prevalence of respiratory diseases owing to the growing aging population and increasing pathogens in the environment has been the key factor driving the chronic obstructive pulmonary disease (COPD) market globally. Pharmaceutical companies have been developing new bio-based medications in combination with bio-technology which promises immense growth opportunities along with sustainable development for COPD market over the next decade.

The global COPD drug market is a multi-billion dollar market which has a history of several decades and has witnessed number of technological advancements and product development over the past few years. Upcoming treatment methodologies such as once-a-day combination products and monoclonal antibodies have created new opportunities for the market growth. The global market for chronic obstructive pulmonary disease (COPD) prescription drugs was valued at $34.9 billion in 2011. This figure is expected to reach $38 billion in 2012 and $47.1 billion in 2017, growing at a five-year compound annual growth rate (CAGR) of 4.4%.

Currently, North America leads the global market for COPD drugs and devices. However, North America and Europe is expected to lose out some of the market share to other emerging regional markets owing to the expiry of several patens of pharmaceutical companies operating in these regions. Asia Pacific is estimated to be the rapid regional market for COPD due to the increased incidence of respiratory diseases in industrial regions. 

Figure 1: Regional scope of COPD

A large decrease in COPD mortality rates COPD deaths fell only slightly, from 3 million in 1990 to 2.8 million in 2010 because the mean age of the population increased. The number of COPD deaths in 2010 would have risen to 5.2 million if the age specific mortality rates had remained constant. Changes in smoking led to only a small increase in age specific mortality rates. Global outlines of mortality are changing, mainly due to three related transformations: an epidemiological transition driven by change in global risks, with falling death rates in childhood associated with infectious disease, a demographic transition with more people surviving into later life, and a health care transition with improved efficacy of both preventive and curative or palliative treatments.

Figure 2: Members Associated with COPD

Associations:

In Italy

Romanian Society of Pneumology

FederASMA e ALLERGIE

Associazione Italiana Pazienti con Apnee del Sonno

Associazione Apnoici Italiani

Amici contro la Sarcoidosi Italia

Società Italiana per le Malattie Respiratorie Infantili

Societa Italiana di Pneumologia

In Europe

European Society of Swallowing Disorders       

European Sleep Research Society

European Federation of Allergy and Airways Diseases Patient Associations

European Idiopathic Pulmonary Fibrosis & Related Disorders Federation

European Pulmonary Hypertension Association

Cystic Fibrosis Europe

British Lung Foundation

June Hancock Mesothelioma Research Fund

British Thoracic Society

Association for Respiratory Technology and Physiology

The Primary Care Respiratory Society UK

European COPD Coalition

European Lung Foundation

In Worldwide

Algerian Society of Pneumology

Asociación Argentina de Medicina Respiratoria

Thoracic Society of Australia and New Zealand

Austrian Society for Pneumology

Belgian Thoracic Society

Sociedade Brasileira de Pneumologia e Tisiologia

Bulgarian Respiratory Society

Canadian Thoracic Society

Chinese Thoracic Society

Croation Respiratory Society

Egyptian Paediatric Pneumology Society

Forum of International Respiratory Societies

Russian Respiratory Society

Peruvian Society of Pneumology

German Center for Lung Research

Figure 3: Universities Associated with COPD

Major Medical universities:

In Italy

Marche Polytechnic University

University of Aosta Valley

University of Bari

Polytechnic University of Bari

Libera Università Mediterranea

University of Sannio

Giustino Fortunato University

University of Bergamo

University of Bologna

University of Brescia

In Europe

University of Nottingham

Imperial College London, United Kingdom

University of Birmingham, United Kingdom

University of Strasbourg

Versailles Saint-Quentin-en-Yvelines University

Albert Ludwig University of Freiburg

Ruprecht Karl University of Heidelberg

Eberhard Karl University of Tübingen

Medical University of Innsbruck

Medical University of Vienna

Belarusian State Medical University

Gomel State Medical University

In Worldwide

Australian National University, Australia

Charles Darwin University Casoria, Australia

Columbia University Medical  Center, United States

Curtin University Bentley, Australia

Dar Al Uloom University, Saudi Arabia

Harvard University, United States

Iqbal Chest Centre, Bangladesh

Johns Hopkins University, Maryland

Leiden University, Netherlands

Linnaeus University, Sweden

Maastricht University, Netherlands

Macquarie University, Australia

McGill University, Canada

Medi7 Bent Leigh, Australia

Tufts University, United States

University of California, San Francisco

University  of California Los Angeles, United States

University of Colorado Boulder, United States

University of Groningen, Netherlands

University of Pittsburgh, Pennsylvania

University of Toronto, Canada

University of Washington, United States

Figure 4: Hospitals Associated with COPD

Hospitals

In Italy

Milan Medical Center

Santa Maria Nuova Hospital

Salvator Mundi International Hospital

Italian Hospital Group

Careggi University Hospital

Cam Hospital Group

Rome American Hospital

San Raffaele Hospital

Sorrento Hospital

In Europe

European Ophtalmology Clinic

South West Acute Hospital

European Medical Center

Hospital Center Jacques Lacarin

Hospital Center Private De L'europe

In Worldwide

National Jewish Health Hospital

Mayo Clinic

Cleveland Clinic

Massachusetts General Hospital

UCSF Medical Center

University of Michigan Hospitals and Health Centers

Barnes-Jewish Hospital

Penn Presbyterian Medical Center

UCLA Medical Center

Johns Hopkins Hospital

Duke University Hospital

UC San Diego Health-UC San Diego Medical Center

Houston Methodist Hospital

Scripps Green Hospital

The success of the 13^th International Chronic Obstructive Pulmonary Disease Conference has given us the prospect to bring the gathering one more time. Conference Series LLC Ltd hosted the COPD Conference 2021 during December 01-02, 2021 Barcelona, Spain. The conference was focused on COPD Research studies with the theme “Freedom to Breathe, Starts with the Knowledge”. The meeting occupied an area of comprehensive discussions on different topics like Pulmonology, Lung Cancer, and Pulmonary hypertension, COPD Exacerbations and Pulmonary Diseases-Treatment and Therapies.

The conference was embarked with an opening ceremony followed by Keynote sessions and followed by lectures delivered by both Honorable Guests and members of the Keynote forum. 

We welcome all the eminent researchers, students and delegate participants to take part in this upcoming conference to witness invaluable scientific discussions and contribute to the future innovations in the field of COPD Research.

For More details: https://copd.insightconferences.com/

Conference Series llc LTD is overwhelmed to announce the commencement of its 14^th International Chronic Obstructive Pulmonary Disease Conference” in the city of Rome, Italy on December 05-06, 2022 at Rome, Italy this extraordinary conference revolves around the theme “Possible innovative ways to cure and Prevent COPD”. We would like to inquire your cordial existence.

For More details:  COPD Conference

Let us meet again @ COPD Conference 2022